PharmaTalkRadio

PharmaTalkRadio

Download on the App Store

PharmaTalkRadio episodes

  • Insights from Tufts CSDD into Evolving Trial Partnerships Models
    About this podcast: 
    Preliminary survey results conducted by the Tufts CSDD focus on the strategic and structural growth of new trial sites and partnerships in bringing trials directly to the local communities. The preliminary survey findings also shed light on the strategic and structural growth of these new trial sites and partnerships, offering valuable insights into the evolving global clinical trial landscape.

    The significant shift towards bringing clinical trials directly to local communities through various innovative models is noteworthy. Many new clinical trial execution models have been introduced during the past decade including site staff embedded within clinical care settings, remote sites, retail pharmacies, urgent care facilities, and mobile units going directly into local communities. 

    This session comes from the 2025 Partnerships with Sites Summit.
    17 min
  • ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma
    About this podcast:
    This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center. 

    Dr Rosenberg focuses on: 
    • The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancer
    • The potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune response
    • Enfortumab vedotin, an ADC targeting Nectin-4
    For more information, go to IO360summit.com.
    20 min
  • Understanding the Immunological Effects of Radiopharmaceuticals
    About this podcast:
    This presentation from the 2025 IO360º Summit focuses on the immunological effects of radiopharmaceuticals, presented by Chaitanya Divgi, Sr Strategic Expert, Therapeutic Innovation, at Novartis. 

    Specifically, this podcast dives deeper into: 
    • An introduction to radioligand therapy
    • A focus on PSMA-targeted radionuclide therapy
    • Prelimary work on the relationship between systemic radiation therapy and immune effects at the tumor level 
    For more information, visit IO360summit.com 
    19 min
  • How J&J Is Integrating Patient Centricity Across the Enterprise
    About this episode:
    In this podcast, Dr Penny Heaton, Global Head of the Johnson and Johnson Office of the Chief Medical Officer, discusses: 
    • J&J’s approach to patient centricity across the enterprise
    • Her thoughts on balancing balancing safety and risk/benefit ratios with more engaged patients and more complex science
    • Moving risk benefit assessments earlier into clinical development and the necessary change management
    • Incorporating multiple streams of data for the purpose of creating medicines that truly address patient needs in the real world
    For more information, go to PatientsasPartnersConference.com.
    26 min
  • Biogen's Nicole Murphy on Drug Delivery Innovation and the Acquisition of Alcyone Therapeutics
    In this podcast, Nicole Murphy, EVP and Head of Pharmaceutical Operations & Technology at Biogen, discusses:
    • Cross-functional collaboration to deliver value
    • How Biogen is using AI to enhance innovation
    • Supply chain simplification
    • Biogen's partnership philosophy as it relates to drug delivery
    • Their recent $2 billion manufacturing investment in the Research Triangle Park
    • And Biogen's acquisition of Alcyone Therapeutics 
    It's an enlightening look into what real leadership in drug delivery, manufacturing and supply chain management looks like. 

    For more information, go to Drug-Delivery.org.
    32 min
  • What to Expect at the 2026 IO360° Summit
    In this podcast, Kate Woda, Conference Director of the Immuno-Oncology 360° Summit, discusses what attendees can expect at the 12th annual event, including key topic areas, session highlights, presenting companies and more.

    For more information about the upcoming event, full agenda and speakers, visit IO360Summit.com.
    5 min
  • CMOs Working Flexibly with Consultants and Fractional Expertise
    This podcast features a panel discussion from the 2025 Chief Medical Officer Summit 360° with CMOs and advisory solutions firms about how CMOs can work with consultants and fractional talent to stay on budget while getting the expertise needed. Specifically:
    • Different profiles of fractional consultants
    • What to look for in a consultant and how to ensure alignment with the team
    • Scoping the role of fractional talent and iterating as company needs evolve
    • How to best work with firms representing fractional talent
    • Advice for CMOs thinking about consulting
    To learn more about the Chief Medical Officer Summit 360°, please visit CMO360.org.
    31 min
  • Principles and Strategies for Designing Best-in-Class Immuno-Oncology ADCs
    About this podcast:
    This podcast dives deep into the fundamentals of antibody-drug conjugate design, specifically focusing on the selection of targeting antibodies, cytotoxic drugs, and linkers. Presenter Dr Deepa Pakianathan highlights key strategies for constructing ADCs and the critical differentiating features that enhance therapeutic efficacy and safety. 

    For more information, go to IO360summit.com.
    18 min
  • How Patient Organizations are Bridging Patient Inclusivity Gaps at the Site-Level
    About this podcast:
    This podcast comes from the 2025 Patients as Partners in Clinical Research conference. 

    This panel discussion demonstrates how patient advocates are bridging the divide at the site level to improve patient representation in clinical trials. More specifically, this podcast focuses on: 
    • Strategies for overcoming limited resources and lack of infrastructure, which can hinder inclusive clinical trial participation
    • Successful models for empowering local leaders and leveraging community-based networks to increase participation
    • Evaluating the impact of outreach and engagement efforts on enrollment representation and overall care equity
    • And more
    For more information, go to PatientsAsPartnersConference.com.
    42 min
  • How Roche Reduced Unnecessary Protocol Amendments to Impact Timeline and Cost
    About this podcast: 
    Liz Thompson, Global Development Leader, Senior Clinical Development Scientist at Roche, presented how the organization had delivered a single, cohesive protocol amendment categorization process to reduce the number of amendments and create a continuous improvement strategy, all to speed up timelines and reduce costs. This presentation comes from the September 2025 DPHARM: Disruptive Innovations to Modernize Clinical Research program. 

    More specifically, Ms Thompson discusses how Roche is: 
    • Leveraging historical amendment data to enable study teams to understand why protocols are being amended
    • Utilizing a visual data science platform to generate insights from data to make better data-driven decisions
    • Applying retrospective learning into current protocols to curb the need for amendments
    • Building in business value 

    For more information, go to DPHARMconference.com.
    14 min

About PharmaTalkRadio

From the publisher's feed

PharmaTalkRadio is an internet radio podcast platform organized and supported by the Conference Forum to give easy and free access to industry professionals, patient advocacy and students in medicine…